EggenerSE, YousufA, WatsonS, WangS, Oto A Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer. J Urol, 2016; 196:1670–1675.
2.
WangAZ, LebastchiAH, O'ConnorLP, et al.Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials. World J Urol, 2021; 39:729–739.
3.
LebastchiAH, GeorgeAK, PolascikTJ, et al.Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: An international multidisciplinary consensus. Eur Urol, 2020; 78:371–378.
4.
BerendsJ, DupatiA, DibiancoJ, GeorgeAK. Focal therapy is a viable treatment for low-risk prostate cancer. J Endourol, 2021; 35:1281–1283.
5.
SuganoD, de Castro AbreuAL, CacciamaniG, GillI, LebastchiA. Focal therapy for low-risk prostate cancer opinion: No. J Endourol, 2021; 35:1284–1287.
6.
BloomJB, GoldSA, HaleGR, et al.“Super-active surveillance”: MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. Gland Surg, 2018; 7:166–187.
7.
AhdootM, LebastchiAH, TurkbeyB, WoodB, PintoPA. Contemporary treatments in prostate cancer focal therapy. Curr Opin Oncol, 2019; 31:200–206.
